SLC35A2 and breast carcinoma: The primary limitation of this work is the retrospective nature of the transcriptome analysis, that may require additional validation in larger scale studies to evaluate the feasibility of SLC35A2 expression as novel biomarker in diagnosis and treament of female breast cancer.